Vetoquinol Wins FDA Approval to Market Felpreva in the United States
Key Facts
Vetoquinol said the U.S. Food and Drug Administration had granted Felpreva marketing approval in the United States, according to a company statement published on November 16, 2026. The authorization covers a broad-spectrum topical parasiticide for cats. The treatment is administered four times a year, according to coverage detailing the announcement. In the United States and Europe, it is available by veterinary prescription and is intended exclusively for cats. The announcement did not specify when it would become commercially available in the U.S. market or provide revenue forecasts there.
The company highlighted the reduction in application frequency while maintaining broad-spectrum treatment as a key advantage. Chief Executive Matthieu Frechin said Felpreva “simplifies parasite control for veterinarians and cat owners through a straightforward solution that combines fewer applications with broad-spectrum treatment and protection.” The description reflects the company’s focus on ease of use and dosing frequency, without estimating demand or the expected financial impact in the United States. The product is applied topically, according to its published details. A veterinary prescription is required to obtain it in both the United States and Europe.
Felpreva combines three active ingredients: tigolaner, emodepside and praziquantel. Under its European authorization, a single dose covers tapeworms, intestinal roundworms, lungworms, fleas, ticks and mites for up to 3 months. These details relate to the scope of the European authorization; the U.S. announcement does not specify in the available evidence whether the coverage terms or label wording in the United States match it. The European Commission granted the product marketing authorization on November 18, 2021, following a positive opinion from the Committee for Veterinary Medicinal Products. The company expected it to become available to veterinarians in Europe in early 2022.
When the European authorization was announced, Vetoquinol described the product as the first topical solution for cats approved in the European Union to treat infestations by internal and external parasites, including tapeworms, for up to 3 months. Frechin said at the time that the authorization was “a pivotal achievement for both Vetoquinol and Felpreva,” describing the treatment as combining ease of use with long-lasting efficacy. This provides background on the product’s launch in Europe ahead of the current U.S. marketing approval. This background alone does not provide an estimate of Felpreva sales or its future contribution to the company’s results. The U.S. approval announcement also does not include a specific commercial launch date.
The approval comes against the backdrop of the company’s latest financial results, with Vetoquinol reporting sales of 525.7 million euros in fiscal 2025. Sales rose 0.2% at constant exchange rates compared with 2024, but fell 2.5% on a reported basis. In the first half of 2026, sales totaled 259 million euros, up 3.4% at constant exchange rates and 0.7% on a reported basis. Core products generated sales of 169 million euros during the period. The published financial data do not link these figures to Felpreva’s U.S. approval or specify expected revenue for the product in that market.